A Randomized Double-Blind Placebo-Controlled Phase 2 Trial Of Dendritic Cell Vaccine ICT-107 In Newly Diagnosed Patients With Glioblastoma
Al Musella's Comments: (This is his personal views and are not necessarily the views of the Musella Foundation!)
This is the final report on the phase 2 trial of ICT-107 for newly diagnosed GBM. It was declared a "failure" because the median survival did not improve enough. However, digging into the details, there are many patients who responded very well, and there were no side effects. As with the other immunotherapy trials, this had a long survival tail which does not get reflected in the mean survival statistics. I still feel this is a worthy treatment to try.
I just heard (and reported in a recent news blast) that this vaccine is making a comeback - it was sold to a new company who hopefully will run another trial in the subgroups that benefitted!
Posted on: 07/20/2019
Click HERE to return to brain tumor news headlines